Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BILR 355 BS with Boosting Agents in Healthy Males
NCT02257008Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2003
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration up to 120 hours, Time to maximum concentration up to 120 hours and 7 more. Started Mar 2003; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02257008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257008.